The B-cell inhibitors market is experiencing robust growth, driven by the rising prevalence of the addressable patient population, which includes indications like IgAN, Multiple Sclerosis, Immune ...

The U.S. Food and Drug Administration has approved the first-in-class TRPM8 receptor agonist Tryptyr (acoltremon ophthalmic ...

The B-cell inhibitors market is experiencing robust growth, driven by the rising prevalence of the addressable patient population, which includes indications like IgAN, Multiple Sclerosis ...

AIIMS Delhi has recorded cases of children as young as 10 and hailing from arid regions suffering from glaucoma, with doctors attributing this to prolonged use of steroid-based eye drops for ...

Lumify Preservative Free relieves redness from minor eye irritations. The new drops are available at most U.S. retailers. Bausch + Lomb launched a preservative-free form of Lumify redness-reducing ...

Cequa is a brand-name eye drop prescribed for dry eye ... which belongs to a group of medications called calcineurin inhibitor immunosuppressants. Cequa comes in eyedrop form as a liquid solution ...

BLU-808 is an investigational oral, highly potent and selective wild-type KIT inhibitor that was developed leveraging Blueprint's expertise in mast cell biology. Wild-type KIT plays a central role ...

The randomized, double-blind, placebo controlled parallel group decentralized trial will enroll 60 patients with idiopathic Mast Cell Activation Syndrome (“MCAS”). Per the protocol, patients will ...